27 October 2020 in Chemistry – A European Journal
Maleimides are essential compounds for drug conjugation reactions via thiols to antibodies, peptides and other targeting units. However, one main drawback is the occurrence of thiol exchange reactions with, for example, glutathione resulting in loss of the targeting ability. A new strategy to overcome such retro‐Michael exchange processes of maleimide–thiol conjugates by stabilization of the thiosuccinimide via a transcyclization reaction is presented. This reaction enables the straightforward synthesis of stable maleimide–thiol adducts essential in drug‐conjugation applications.
14 March 2019 in Angewandte Chemie International Edition
Due to their high kinetic inertness and consequently reduced side reactions with biomolecules, PtIV complexes are considered to define the future of anticancer platinum drugs. The aqueous stability of a series of biscarboxylato PtIV complexes was studied under physiologically relevant conditions. Unexpectedly and in contrast to the current chemical understanding, especially oxaliplatin and satraplatin complexes underwent fast hydrolysis in equatorial position (even in cell culture medium and serum). Notably, the resulting hydrolysis products strongly differ in their reduction kinetics, a crucial parameter for the activation of PtIV drugs, which also changes the anticancer potential of the compounds in cell culture. The discovery that intact PtIV complexes can hydrolyze at equatorial position contradicts the dogma on the general kinetic inertness of PtIV compounds and needs to be considered in the screening and design for novel platinum‐based anticancer drugs.
28 June 2023 in Inorganic Chemistry Frontiers
Platinum(IV) prodrugs are a promising class of anticancer agents designed to overcome the limitations of conventional platinum(II) therapeutics. In this work, we present oxaliplatin(IV)-based complexes, which upon reduction, release acetylsalicylic acid (aspirin), known for its antitumor activity against colon cancer and currently investigated in combination with oxaliplatin in a phase III clinical study. Comparison with a recently reported cisplatin analog (asplatin) revealed a massive increase in reduction stability for the oxaliplatin complex in mouse serum. This was in line with the cell culture data indicating the desired prodrug properties for the newly synthesized complex. For in vivo studies, a new derivative containing an albumin-binding maleimide unit was synthesized. Indeed, distinctly longer plasma half-life as well as higher tumor accumulation in comparison to asplatin and oxaliplatin were observed, also leading to significantly higher antitumor activity and overall survival of CT26 tumor-bearing mice.
6 December 2023 in Inorganic Chemistry Frontiers
An albumin-binding cisplatin( iv )-gemcitabine complex was step-by-step improved based on stability, reduction, albumin-binding and in vivo data yielding a carboplatin( iv ) complex with distinctly improved overall survival and anticancer activity.
13 October 2023 in Angewandte Chemie International Edition
Platinum(IV) prodrugs are highly interesting alternatives to platinum(II) anticancer therapeutics due to their increased tumor selectivity and reduced side effects. In contrast to the established theory, we recently observed that the equatorial ligand(s) of e.g. oxaliplatin(IV) complexes can be hydrolyzed with formation of [(DACH)Pt(OH eq ) 2 (OAc ax ) 2 ]. In the work presented here, we investigated the reactivity and synthetic usability of this complex to be exploited as a precursor for the development of novel platinum(IV) complexes, not able to be synthesized by conventional protocols. Indeed, we could substitute the equatorial hydroxido ligand(s) e.g. by one or two monodentate biotin ligands (which would be oxidized under standard methods). The formed complexes turned out to be very stable with slow ligand release after reduction, ideal for long‐circulating tumor‐targeting strategies. Therefore, two platinum(IV) complexes with equatorial maleimides, capable of exploiting serum albumin as a natural nanocarrier, were synthesized as well. The complexes showed massively prolonged plasma half‐life and distinctly improved anticancer activity in vivo compared to oxaliplatin. Taken together, the newly developed synthetic platform allows the simple and specific insertion of equatorial ligands into platinum(IV) complexes. This will enable the attachment of three different (bioactive) moieties generating targeted triple‐action platinum(IV) prodrugs within one single platinum complex.
14 March 2019 in Angewandte Chemie
PtIV‐Komplexe gelten aufgrund ihrer hohen kinetischen Inertheit und der folglich reduzierten Nebenreaktionen mit Biomolekülen als die Zukunft der Platintherapeutika. In dieser Arbeit wurde unter physiologisch relevanten Bedingungen die Stabilität einer Reihe von PtIV‐Biscarboxylatokomplexen in wässriger Lösung untersucht. Entgegen des derzeitigen chemischen Kenntnisstandes zeigten (sogar in Zellkulturmedium und Serum) vor allem Oxaliplatin‐ und Satraplatinkomplexe eine schnelle äquatoriale Hydrolyse. Die gebildeten Hydrolyseprodukte unterscheiden sich besonders stark in ihrer Reduktionskinetik, einem entscheidenden Parameter für die Aktivierung von PtIV‐Medikamenten, welcher auch mit der zytotoxischen Effizienz der Verbindungen in der Zellkultur korreliert. Die Entdeckung, dass intakte PtIV‐Komplexe an äquatorialer Position hydrolysiert werden können, widerspricht dem Dogma hinsichtlich der allgemeinen kinetischen Inertheit von PtIV‐Verbindungen und muss beim Screening und der Entwicklung neuer platin‐basierter Krebsmedikamente berücksichtigt werden.